Table 1.
GMCSF-MOG prevented a subsequent bout of EAE induced by challenge with MOG35-55 in CFA
| Exp. # | Pre-treatmenta | Mean cum. scoreb | Median cum. scoreb | Mean max. scoreb |
Median max. scoreb | % mean initial weightb | Incidence of EAEc |
Mean # days with severe EAEc |
|---|---|---|---|---|---|---|---|---|
| 1 | Saline | 102.6 ± 48.9 | 115.5 | 3.5 ± 1.4 | 4.0 | 77.9% | 7 of 8 | 18.3 ± 7.6 |
| MOG | 103.8 ± 16.6 | 106.3 | 4.0 ± 0.0 | 4.0 | 72.5% | 8 of 8 | 18.3 ± 1.8 | |
| GMCSF-MOG | 18.3 ± 40.9 | 0.0 | 0.8 ± 1.8 | 0.0 | 93.6% | 1 of 5 | 3.6 ± 8.0 | |
| TTV vs saline | p = 0.05 | p = 0.003 | p = 0.015 | p = 0.032 | p = 0.002 | |||
| TTV vs MOG | p = 0.02 | p = 0.001 | p = 0.001 | p = 0.007 | p = 0.002 | |||
| 2 | Saline | 41.2 ± 19.4 | 44.8 | 4.0 ± 0.0 | 4.0 | 84.2% | 8 of 8 | 10.1 ± 5.8 |
| MOG | 40.6 ± 24.3 | 45.8 | 3.4 ± 1.5 | 4.0 | 92.7% | 8 of 8 | 8.9 ± 6.7 | |
| GMCSF-MOG | 0.0 ± 0.0 | 0.0 | 0.0 ± 0.0 | 0.0 | 103.0% | 0 of 8 | 0.0 ± 0.0 | |
| TTV vs saline | p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | p = 0.002 | |||
| TTV vs MOG | p < 0.001 | p < 0.001 | p = 0.021 | p < 0.001 | p = 0.007 | |||
a C57BL/6 mice were treated with 2 nmoles of GMCSF-MOG, 2 nmoles of MOG35-55, or saline. Injections were subcutaneous in saline and were given on days -21, -14, and -7 (total combined dose of 6 nmoles) before active challenge on day 0 (200 ug of MOG35-55 in CFA with i.p. injections of Pertussis toxin on days 0 and 2). Table 1 and Figure 3 represent the same experiments. Experiments 1 and 2 correspond to the data shown in Figure 3A-B and 3C-D, respectively.
b Cumulative scores were calculated by summing daily scores for each mouse. Maximal scores were calculated as the most severe EAE score for each mouse. Percent initial body weight was calculated as the minimum weight recorded between day 7 and the end of the experiment divided by the maximum weight recorded from day 0 through day 7. For all tables, the mean cumulative and mean maximal scores included all mice within a group, even those not afflicted by EAE. That is, the score of zero representing mice that did not exhibit EAE was included in the calculation of the respective mean values. Differences in median values for cumulative and maximal scores were analyzed by nonparametric ANOVA based on ranked scores. Differences in mean values for percent initial body weight and "number of days with severe EAE" were assessed by parametric ANOVA. ANOVA was interpreted with the Bonferroni post hoc test. Incidence of EAE was analyzed pair-wise by Fisher's Exact Test.
c Severe EAE was defined as hindlimb paresis or paralysis (clinical score of 3.0 or greater).